Aztrezenica have pulled back 16% on recent share price mostly due to issues with their partnered phase 3 lung cancer drug that was supposed to be an alternative to chemotherapy, they have been light on technical data but numerous grade 5 reactions have occurred that’s pharma speak for fatalities. This AZ drug would have been a replacement for standard Docetaxel so does this mean that Starpharma’s Dendrimer enhanced Docetaxel now becomes a much better prospect than previously. It’s a question worth asking because if the Aztrezenica drug is dropped or even significantly restricted in use this could make licensing DEP Docetaxel an attractive option for some Pharma or even AZ after all Starpharma have by all accounts solved the side effects issues any retention or improvement in efficacy will make things even more interesting imo
SPL Price at posting:
35.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)